CA1116083A - Pharmaceutical preparations - Google Patents
Pharmaceutical preparationsInfo
- Publication number
- CA1116083A CA1116083A CA305,647A CA305647A CA1116083A CA 1116083 A CA1116083 A CA 1116083A CA 305647 A CA305647 A CA 305647A CA 1116083 A CA1116083 A CA 1116083A
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical preparation
- preparation according
- heparin
- zinc ions
- preparations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 16
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229920000669 heparin Polymers 0.000 claims abstract description 24
- 229960002897 heparin Drugs 0.000 claims abstract description 24
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002253 acid Substances 0.000 claims abstract description 12
- 239000000499 gel Substances 0.000 claims abstract description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 11
- 150000004676 glycans Polymers 0.000 claims abstract description 10
- 239000005017 polysaccharide Substances 0.000 claims abstract description 10
- 229920000642 polymer Polymers 0.000 claims abstract description 9
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims abstract description 9
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 9
- 230000000699 topical effect Effects 0.000 claims abstract description 9
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims abstract description 8
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims abstract description 8
- 229920001213 Polysorbate 20 Polymers 0.000 claims abstract description 7
- 239000006071 cream Substances 0.000 claims abstract description 5
- 239000002674 ointment Substances 0.000 claims abstract description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 9
- 230000000840 anti-viral effect Effects 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 150000003752 zinc compounds Chemical class 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 16
- 208000015181 infectious disease Diseases 0.000 abstract description 6
- 239000000243 solution Substances 0.000 abstract description 6
- 241001529453 unidentified herpesvirus Species 0.000 abstract description 5
- 208000001688 Herpes Genitalis Diseases 0.000 abstract description 4
- 201000004946 genital herpes Diseases 0.000 abstract description 4
- 206010062639 Herpes dermatitis Diseases 0.000 abstract description 2
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 150000004804 polysaccharides Polymers 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- -1 polyoxy Polymers 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000700605 Viruses Species 0.000 description 7
- 239000013543 active substance Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 150000005846 sugar alcohols Polymers 0.000 description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 5
- 235000009529 zinc sulphate Nutrition 0.000 description 5
- 239000011686 zinc sulphate Substances 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102100027085 Dual specificity protein phosphatase 4 Human genes 0.000 description 3
- 101001057621 Homo sapiens Dual specificity protein phosphatase 4 Proteins 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229910021653 sulphate ion Inorganic materials 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- JCYWCSGERIELPG-UHFFFAOYSA-N imes Chemical class CC1=CC(C)=CC(C)=C1N1C=CN(C=2C(=CC(C)=CC=2C)C)[C]1 JCYWCSGERIELPG-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000002731 mercury compounds Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229950005175 sudoxicam Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- RVUXIPACAZKWHU-UHFFFAOYSA-N sulfuric acid;heptahydrate Chemical compound O.O.O.O.O.O.O.OS(O)(=O)=O RVUXIPACAZKWHU-UHFFFAOYSA-N 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU77562 | 1977-06-17 | ||
| LU77562A LU77562A1 (de) | 1977-06-17 | 1977-06-17 | Verfahren zur herstellung von neuen pharmazeutischen praeparaten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1116083A true CA1116083A (en) | 1982-01-12 |
Family
ID=19728615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA305,647A Expired CA1116083A (en) | 1977-06-17 | 1978-06-16 | Pharmaceutical preparations |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4465666A (https=) |
| EP (1) | EP0000133B1 (https=) |
| JP (1) | JPS548727A (https=) |
| AU (1) | AU522600B2 (https=) |
| CA (1) | CA1116083A (https=) |
| DE (1) | DE2861070D1 (https=) |
| IE (1) | IE47096B1 (https=) |
| IT (1) | IT1105718B (https=) |
| LU (1) | LU77562A1 (https=) |
| NZ (1) | NZ187598A (https=) |
| ZA (1) | ZA783480B (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU77562A1 (de) * | 1977-06-17 | 1979-03-26 | Ciba Geigy Ag | Verfahren zur herstellung von neuen pharmazeutischen praeparaten |
| EP0012115A1 (de) * | 1978-12-04 | 1980-06-11 | Ciba-Geigy Ag | Pharmazeutische Präparate zur topischen Behandlung von Virusinfektionen |
| GB2080682B (en) * | 1980-07-30 | 1984-03-28 | Ciba Geigy Ag | Antiherpetically active lipstick |
| DE3273138D1 (en) * | 1981-06-02 | 1986-10-16 | Eupan Corp | Eustatic composition for nonspecifically facilitating and amplifying the generalized homeostatic regulation and maintenance, compensation and repair in living organisms |
| FR2548023B1 (fr) * | 1983-06-16 | 1987-06-26 | Victoria State | Medicament veterinaire et solution de bain de pieds pour le traitement du pietin des ovins |
| CA1291034C (en) * | 1987-10-19 | 1991-10-22 | Mostafa S. Fahim | Composition for promoting epithelial regeneration |
| US4661354A (en) * | 1984-06-21 | 1987-04-28 | Finnerty Edmund F | Topical treatment of herpes simplex with a zinc sulfate-camphor water solution |
| US4895727A (en) * | 1985-05-03 | 1990-01-23 | Chemex Pharmaceuticals, Inc. | Pharmaceutical vehicles for exhancing penetration and retention in the skin |
| EP0243352A1 (en) * | 1985-10-21 | 1987-11-04 | SERGIO, William | Method for reducing the risk or probability of infection from the aids virus (htlv-iii/lav/arv) |
| US5668116A (en) * | 1987-03-19 | 1997-09-16 | Anthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
| ES2024641B3 (es) * | 1987-05-20 | 1992-03-01 | Kk Ueno Seiyaku Oyo Kenkyujo | Preservativo. |
| US5159069A (en) * | 1988-12-20 | 1992-10-27 | Yamanouchi Pharmaceutical Co., Ltd. | Sulfated tannins and their salts |
| CA2026990C (en) * | 1989-02-10 | 1996-06-25 | Taiho Pharmaceutical Co., Ltd. | Anti-hiv agent |
| US5785054A (en) * | 1989-06-06 | 1998-07-28 | Kelly; Patrick D. | Genital lubricant with zinc salt, labelled as anti-viral agent |
| US5208031A (en) * | 1989-06-06 | 1993-05-04 | Kelly Patrick D | Sexual lubricants containing zinc as an anti-viral agent |
| US5545673A (en) * | 1989-06-06 | 1996-08-13 | Kelly; Patrick D. | Method for reducing risk of infection by sexually transmitted viruses |
| US5599551A (en) * | 1989-06-06 | 1997-02-04 | Kelly; Patrick D. | Genital lubricants containing zinc as an anti-viral agent |
| EP0402078A3 (en) * | 1989-06-06 | 1991-07-31 | Patrick Daniel Kelly | Sexual lubricants containing zinc as an anti-viral agent |
| US5482053A (en) * | 1989-06-06 | 1996-01-09 | Kelly; Patrick D. | Condom lubricants containing zinc as an anti-viral agent |
| US5624675A (en) * | 1989-06-06 | 1997-04-29 | Kelly; Patrick D. | Genital lubricants containing zinc salts to reduce risk of HIV infection |
| AU1052492A (en) * | 1991-01-31 | 1992-08-06 | Farmitalia Carlo Erba S.R.L. | Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent |
| US5705178A (en) * | 1991-05-31 | 1998-01-06 | Gliatech, Inc. | Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers |
| US5605938A (en) * | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| US5980477A (en) * | 1991-07-29 | 1999-11-09 | Patrick Kelly | Genital lubricants with zinc salts as anti-viral additives |
| US6321750B1 (en) * | 1993-05-03 | 2001-11-27 | Patrick D. Kelly | Condom lubricants with zinc salts as anti-viral additives |
| US5662919A (en) * | 1994-11-21 | 1997-09-02 | Alcon Laboratories, Inc. | Sulfated polyvinyl alcohol polymers to stabilize pharmaceutical drug compounds |
| US5837266A (en) * | 1996-04-30 | 1998-11-17 | Hydromer, Inc. | Composition, barrier film, and method for preventing contact dermatitis |
| SE507028C2 (sv) * | 1996-08-06 | 1998-03-16 | Medicarb Ab | Ny medicinsk användning |
| EP0948347A4 (en) * | 1997-07-16 | 2000-08-30 | Sophie Chen | ANTI-VIRALS AND ANTI-TUMOR ACTIVE SUBSTANCES |
| US6187768B1 (en) | 1999-06-01 | 2001-02-13 | Becton, Dickinson And Company | Kit for flushing medical devices and method of preparation |
| US6558710B1 (en) | 1999-06-14 | 2003-05-06 | Helen Rebecca Godfrey | Topical zinc compositions and methods of use |
| US6977248B1 (en) * | 1999-08-25 | 2005-12-20 | Massachusetts Institute Of Technology | Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry |
| US6475526B1 (en) | 2001-06-05 | 2002-11-05 | Jeffrey B. Smith | Zinc containing compositions for anti-viral use |
| US20080274209A1 (en) * | 2002-11-04 | 2008-11-06 | Integritas Pharma, Inc. | Methods of treating inflammation |
| US6855341B2 (en) * | 2002-11-04 | 2005-02-15 | Jeffrey B. Smith | Anti-viral compositions and methods of making and using the anti-viral compositions |
| US7968122B2 (en) * | 2003-12-10 | 2011-06-28 | Adventrx Pharmaceuticals, Inc. | Anti-viral pharmaceutical compositions |
| US20060147559A1 (en) * | 2005-01-06 | 2006-07-06 | National Research Laboratories, Ltd. | Methods for Altering the Mineral Content of Foods |
| WO2007089267A1 (en) | 2006-02-03 | 2007-08-09 | Jr Chem, Llc | Anti-aging treatment using copper and zinc compositions |
| US7897800B2 (en) | 2006-02-03 | 2011-03-01 | Jr Chem, Llc | Chemical compositions and methods of making them |
| US7687650B2 (en) | 2006-02-03 | 2010-03-30 | Jr Chem, Llc | Chemical compositions and methods of making them |
| US7867522B2 (en) | 2006-09-28 | 2011-01-11 | Jr Chem, Llc | Method of wound/burn healing using copper-zinc compositions |
| US8273791B2 (en) | 2008-01-04 | 2012-09-25 | Jr Chem, Llc | Compositions, kits and regimens for the treatment of skin, especially décolletage |
| CA2750636C (en) | 2009-01-23 | 2017-07-25 | Jr Chem, Llc | Rosacea treatments and kits for performing them |
| EP2283805A1 (en) | 2009-07-28 | 2011-02-16 | Sirvis BV | Compositions comprising a zinc containing compound dissolved in a hydrophobic phase |
| IT1400232B1 (it) * | 2010-05-07 | 2013-05-24 | Advance Holdings Ltd | Composizione farmaceutica topica comprendente eparina |
| US8952057B2 (en) | 2011-01-11 | 2015-02-10 | Jr Chem, Llc | Compositions for anorectal use and methods for treating anorectal disorders |
| DE102011077393A1 (de) * | 2011-06-10 | 2012-12-13 | Johannes Reinmüller | Antiinfektives Mittel |
| KR20190095937A (ko) | 2016-12-11 | 2019-08-16 | 시너지 더마톨로지 리미티드 | 설페이트화된 다당류를 포함하는 조성물 |
| CN110041124A (zh) * | 2019-04-23 | 2019-07-23 | 浙江工业大学 | 一种水稻专用富锌营养液及其用于生产富锌大米的方法 |
| FR3163569A1 (fr) | 2024-06-24 | 2025-12-26 | L'oreal | Procédé de traitement des matières kératiniques mettant en œuvre au moins un composé polyester à fonctions acétoacétates |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2715711A1 (de) * | 1977-04-07 | 1978-10-19 | Robugen Gmbh | Topisch anwendbares arzneimittel zur behandlung von viruserkrankungen der haut und der schleimhaut |
| LU77562A1 (de) * | 1977-06-17 | 1979-03-26 | Ciba Geigy Ag | Verfahren zur herstellung von neuen pharmazeutischen praeparaten |
-
1977
- 1977-06-17 LU LU77562A patent/LU77562A1/de unknown
-
1978
- 1978-06-09 DE DE7878100133T patent/DE2861070D1/de not_active Expired
- 1978-06-09 EP EP78100133A patent/EP0000133B1/de not_active Expired
- 1978-06-15 IT IT49884/78A patent/IT1105718B/it active
- 1978-06-15 AU AU37153/78A patent/AU522600B2/en not_active Expired
- 1978-06-16 NZ NZ187598A patent/NZ187598A/xx unknown
- 1978-06-16 IE IE1212/78A patent/IE47096B1/en not_active IP Right Cessation
- 1978-06-16 CA CA305,647A patent/CA1116083A/en not_active Expired
- 1978-06-16 ZA ZA00783480A patent/ZA783480B/xx unknown
- 1978-06-17 JP JP7274678A patent/JPS548727A/ja active Granted
-
1981
- 1981-10-30 US US06/316,585 patent/US4465666A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0000133B1 (de) | 1981-09-16 |
| IE47096B1 (en) | 1983-12-14 |
| US4465666A (en) | 1984-08-14 |
| DE2861070D1 (en) | 1981-12-03 |
| IT7849884A0 (it) | 1978-06-15 |
| LU77562A1 (de) | 1979-03-26 |
| JPS6225126B2 (https=) | 1987-06-01 |
| ZA783480B (en) | 1979-07-25 |
| NZ187598A (en) | 1981-03-16 |
| AU522600B2 (en) | 1982-06-17 |
| AU3715378A (en) | 1979-12-20 |
| EP0000133A1 (de) | 1979-01-10 |
| IE781212L (en) | 1978-12-17 |
| IT1105718B (it) | 1985-11-04 |
| JPS548727A (en) | 1979-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1116083A (en) | Pharmaceutical preparations | |
| CA1146859A (en) | Pharmaceutical preparations containing zinc | |
| US4670185A (en) | Aqueous vesicle dispersion having surface charge | |
| US4822601A (en) | Cosmetic base composition with therapeutic properties | |
| CA1124179A (en) | Method for treating acne vulgaris and compositions useful for that purpose | |
| JPH11322591A5 (https=) | ||
| EP0138029A2 (en) | Pharmaceutical composition | |
| US4946832A (en) | Cosmetic base composition with therapeutic properties | |
| US5380754A (en) | Topical composition enhancing healing of viral lesions | |
| US4034114A (en) | Treatment of skin keratoses with retinal | |
| US8642053B2 (en) | Potentiated topical composition | |
| CN114522133A (zh) | 一种抑菌微乳液及其制备方法和应用、保湿水、保湿乳液、保湿膏霜及其制备方法 | |
| KR910002442A (ko) | 안구질환을 치료하는 방법 및 제약학적 조성물 | |
| EP0294914A2 (en) | Nedocromil for the treatment of dermatological disorders | |
| AU2002339819A1 (en) | Potentiated topical composition | |
| JPH09291012A (ja) | 消炎性皮膚化粧料 | |
| EP0213632B1 (en) | Moisture-retaining preparation for dermal use | |
| JPH09176034A (ja) | 皮膚外用剤 | |
| Dodd et al. | Surface-active agents as ointment bases | |
| DE69634536T2 (de) | 2,4-dichlorbenzylalkohol und amylmetakresol gegen hiv-infektion | |
| US3019162A (en) | Cinchophen-hydrocortisone topical compositions | |
| CA1224152A (en) | Topical treatment of acne | |
| JP3516792B2 (ja) | 皮膚外用剤 | |
| CA1227754A (en) | Use of tolnaftate in the treatment of herpes labialis | |
| CN109820772A (zh) | 抗菌护肤湿巾及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |